drugset / Trial / NCT00440050

DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease

NCT00440050

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether chronic DHA (Docosahexaenoic Acid) supplementation slows the progression of cognitive and functional decline in mild to moderate Alzheimer's disease (AD).

Timeline

Start
2007-02
Primary completion
2009-05
Completion
2009-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject DOCONEXENT Other / unclassified 2 g Oral

Indications